A leading contributor of science and knowledge through discoveries.

← Back to Profiles

Grant Hatch PhD

Currently accepting students.

Current Position

Canada Research Chair in Molecular Cardiolipin Metabolism


B.Sc. 4Yr U of Winnipeg; M.Sc. Biochemistry U of Saskatchewan; Ph.D. Biochemistry U Of Manitoba; Postdoctoral Fellow Biochemistry U of Alberta.

Cardiolipin is not a well-known word or thing but it s integral to all mammalian cells and by studying it, Dr. Grant Hatch is hoping to find some novel ways to exploit it for good. Phospholipids are fatty compounds essential in maintaining the proper function of cellular membranes. Cardiolipin is a major phospholipid found in heart and other cells. Hatch is an expert in the field of cardiolipin biosynthesis and remodeling in mammalian cells and his lab at the University of Manitoba is one of only a few in the world carrying out this kind of cardiolipin research.

Hatch was prairie born and prairie educated, having received his B.Sc. from the University of Winnipeg, his M.Sc. from the University of Saskatchewan, and his PhD from the University of Manitoba in 1989. He then went to the University of Alberta for a Post Doctoral Fellowship, which he completed in 1992. He then came to the University of Manitoba to assume the post of Assistant Professor. He rose through the ranks to become Professor in 2002. He became a Tier 1 Canada Research Chair in 2006. Hatch has won numerous career awards from the Manitoba Health Research Council, Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research and the University of Manitoba, and he has published over 100 refereed articles, reviews and book chapters.

Hatch relocated his laboratory to CHRIM in June 2011 and is looking forward to fruitful and productive collaborations with the CHRIM community.

Research Focus:

Studies on the regulation of phospholipid and lipid & lipoprotein metabolism with a focus on the childhood diseases Barth Syndrome & Persistant Pulmonary Hypertension of the Newborn.

Dr. Hatch s laboratory is studying whether increasing the cells ability to remodel cardiolipin will aid in the treatment of Barth Syndrome, a rare genetic disease that weakens the heart. He and his colleagues are guided by the belief that their work may lead to new therapies to treat a range of diseases and disorders from Barth Syndrome to heart failure. A few years ago Hatch received a small grant from the Childrens Hospital Foundation and subsequently a CHRIM grant to study Barth Syndrome. Based upon the foundation of these grants he published several papers on Barth Syndrome and was subsequently successful in obtaining several grants from the Barth Syndrome Foundation USA and most recently a five year grant from the Canadian Institutes of Health Research to continue with his studies.